Mechanisms of cancer drug resistance
- PMID: 11818492
- DOI: 10.1146/annurev.med.53.082901.103929
Mechanisms of cancer drug resistance
Abstract
The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common. The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anticancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.
Similar articles
-
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.Drug Resist Updat. 2020 May;50:100682. doi: 10.1016/j.drup.2020.100682. Epub 2020 Feb 7. Drug Resist Updat. 2020. PMID: 32087558
-
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment.Cell Death Dis. 2013 Oct 10;4(10):e838. doi: 10.1038/cddis.2013.350. Cell Death Dis. 2013. PMID: 24113172 Free PMC article. Review.
-
Resistance mechanisms to cancer chemotherapy.Front Biosci. 2008 May 1;13:5138-54. doi: 10.2741/3070. Front Biosci. 2008. PMID: 18508576 Review.
-
Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities.Curr Drug Metab. 2019;20(14):1114-1131. doi: 10.2174/1389200221666200103111539. Curr Drug Metab. 2019. PMID: 31902353 Review.
-
Mucins and tumor resistance to chemotherapeutic drugs.Biochim Biophys Acta. 2014 Aug;1846(1):142-51. doi: 10.1016/j.bbcan.2014.04.008. Epub 2014 Apr 29. Biochim Biophys Acta. 2014. PMID: 24785432 Review.
Cited by
-
Extracellular Vesicles in Chemoresistance.Subcell Biochem. 2021;97:211-245. doi: 10.1007/978-3-030-67171-6_9. Subcell Biochem. 2021. PMID: 33779919
-
Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.ACS Nano. 2013 Feb 26;7(2):994-1005. doi: 10.1021/nn3044066. Epub 2013 Jan 4. ACS Nano. 2013. PMID: 23289892 Free PMC article.
-
Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor.Cell Chem Biol. 2021 Sep 16;28(9):1258-1270.e13. doi: 10.1016/j.chembiol.2021.04.004. Epub 2021 Apr 27. Cell Chem Biol. 2021. PMID: 33910023 Free PMC article.
-
Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1.Sci Rep. 2016 Jun 22;6:28403. doi: 10.1038/srep28403. Sci Rep. 2016. PMID: 27329817 Free PMC article.
-
Current progress for the use of miRNAs in glioblastoma treatment.Mol Neurobiol. 2013 Dec;48(3):757-68. doi: 10.1007/s12035-013-8464-0. Epub 2013 Apr 28. Mol Neurobiol. 2013. PMID: 23625340 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
